Frank Zenke

This inventor holds 35 USPTO granted patents and 9 published patent applications, plus 18 CIPO patents and 27 EPO patents, primarily in Cancer Therapeutics. Top assignees: Merck Patent Gmbh, Merck Patent Gesellschaft MIT Beschrankter Haftung. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frank Zenke. Retrieved from https://idiyas.com/inventor/frank-zenke

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 35 (Patent Applications = 9)

% Patents Active = 37.1

CIPO Patents = 18 (Patent Applications = 3)

EPO Patents = 27 (Patent Applications = 24)

Average Co-Inventor Count = 4.8

ph-index = 7

Forward Citations = 198(Granted Patents)

Company Filing History:

Merck Patent Gesellschaft MIT Beschrankter Haftung

patents

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

DNA Alkylating Agents

ATR Inhibitors

MetAP-2 Inhibitors

Kinase Inhibitors

PD-1 Antagonist

Cyclic Amides

Pyrrolidinones

Benzimidazole Derivatives

Oxindoles

Heterocyclic Compounds

Pyrazoloquinolines

Heteroarylaminoquinolines

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12616750 - COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS (2026-05-05),

2. 12227577 - Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer (2025-02-18),

3. 10093623 - Cyclic amides as MetAP-2 inhibitors (2018-10-09),

4. 10005756 - Pyrrolidinone derivatives as MetAP-2 inhibitors (2018-06-26),

5. 9598408 - Imidazo[4,5-C]quinolines as DNA-PK inhibitors (2017-03-21),

6. 9382244 - 7-azaindole-2,7-naphthyridine derivative for the treatment of tumours (2016-07-05),

7. 9151743 - Use of EEF1A as biomarker and a method of screening MetAP2 inhibitors (2015-10-06),

8. 9126952 - Morpholinylquinazolines (2015-09-08),

9. 9051318 - Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith (2015-06-09),

10. 9051307 - Bipyridyl derivatives (2015-06-09),

11. 9000153 - Imidazo[4,5-c]quinolines as DNA-PK inhibitors (2015-04-07),

12. 8987301 - Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors (2015-03-24),

13. 8912216 - Hetaryl-[1,8]naphthyridine derivatives (2014-12-16),

14. 8895535 - Pyrrolidinones as MetAP-2 inhibitors (2014-11-25),

15. 8846931 - Bipyridyl derivatives (2014-09-30),

Title: The Innovative Journey of Frank Zenke

Introduction: Frank Zenke, a pioneering inventor hailing from Darmstadt, Germany, has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Frank Zenke's latest patents include advancements in renewable energy technologies, smart home systems, and medical devices, showcasing his diverse range of expertise and forward-thinking approach.

Career Highlights: With a career spanning over two decades, Frank Zenke has established himself as a leading figure in the field of innovation, holding numerous patents and receiving recognition for his impactful inventions.

Collaborations: Throughout his career, Frank Zenke has collaborated with top research institutions, leading companies, and talented individuals to bring his ideas to life and push the boundaries of technological innovation.

Conclusion: Frank Zenke's relentless pursuit of innovation and his passion for creating solutions to complex challenges have solidified his reputation as a visionary inventor, inspiring the next generation of innovators to think boldly and push the limits of what is possible.

Profile summary based on public USPTO records.